Search Results - "Lichtneckert, M"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    P-139Monitoring of erlotinib plasma concentrations after long time administration of 100 mg in advanced pancreatic cancer patients

    P-139Monitoring of erlotinib plasma concentrations after long time administration of 100 mg in advanced pancreatic cancer patients by Sahmanovic, A, Buchner, P, Lichtneckert, M, Dittrich, C, Farkouh, A, Gruber, A, Baroian, N, Kitzmueller, M, Czejka, M

    Published in Annals of oncology (01-06-2016)
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    2098 Assessment of pharmacokinetic (PK) interaction between cetuximab (CTX) and capecitabine (CCB) or oxaliplatin (OX) in metastatic colorectal cancer (mCRC) patients (pts) (AGMT_CAPECET_PK)

    2098 Assessment of pharmacokinetic (PK) interaction between cetuximab (CTX) and capecitabine (CCB) or oxaliplatin (OX) in metastatic colorectal cancer (mCRC) patients (pts) (AGMT_CAPECET_PK) by Schreiber, V, Kitzmueller, M, Buchner, P, Weissenboeck, N, Lichtneckert, M, Greil, R, Geiler, H, Czejka, M, Dittrich, C

    Published in European journal of cancer (1990) (01-09-2015)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    P-139 Monitoring of erlotinib plasma concentrations after long time administration of 100 mg in advanced pancreatic cancer patients

    P-139 Monitoring of erlotinib plasma concentrations after long time administration of 100 mg in advanced pancreatic cancer patients by Sahmanovic, A., Buchner, P., Lichtneckert, M., Dittrich, C., Farkouh, A., Gruber, A., Baroian, N., Kitzmueller, M., Czejka, M.

    Published in Annals of oncology (01-06-2016)
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    701PPHASE IB TRIAL TO EVALUATE CAPECITABINE (C), ERLOTINIB (E), AND BEVACIZUMAB (B) IN PATIENTS (PTS) WITH UNRESECTABLE AND/OR METASTATIC PANCREATIC CANCER (UMPC) – PRELIMINARY RESULTS OF THE REBECA TRIAL INCLUDING PHARMACOKINETICS (PK) AND CIRCULATING TUMOR CELLS (CTCS)

    701PPHASE IB TRIAL TO EVALUATE CAPECITABINE (C), ERLOTINIB (E), AND BEVACIZUMAB (B) IN PATIENTS (PTS) WITH UNRESECTABLE AND/OR METASTATIC PANCREATIC CANCER (UMPC) – PRELIMINARY RESULTS OF THE REBECA TRIAL INCLUDING PHARMACOKINETICS (PK) AND CIRCULATING TUMOR CELLS (CTCS) by Dittrich, C., Buchner, P., Sahmanovic, A., Königsberg, R., Lichtneckert, M., Nirnberger, G., Czejka, M., Geissler, K.

    Published in Annals of oncology (01-09-2014)
    “…Abstract Aim: UMPC represents an unmet therapeutic need. Maximum tolerated dose (MTD), PK, safety, and doses recommended for phase II (RPIID) of CEB were…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  5. 5
    Phase Ib Trial to Evaluate Capecitabine (C), Erlotinib (E), and Bevacizumab (B) in Patients (Pts) with Unresectable and/or Metastatic Pancreatic Cancer (Umpc) – Preliminary Results of the Rebeca Trial Including Pharmacokinetics (Pk) and Circulating Tumor Cells (Ctcs)

    Phase Ib Trial to Evaluate Capecitabine (C), Erlotinib (E), and Bevacizumab (B) in Patients (Pts) with Unresectable and/or Metastatic Pancreatic Cancer (Umpc) – Preliminary Results of the Rebeca Trial Including Pharmacokinetics (Pk) and Circulating Tumor Cells (Ctcs) by Dittrich, C., Buchner, P., Sahmanovic, A., Königsberg, R., Lichtneckert, M., Nirnberger, G., Czejka, M., Geissler, K.

    Published in Annals of oncology (01-09-2014)
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: